Azacytidine During Anti-tuberculosis Therapy

"In Phase Ib dose escalation stage, 24 participants will receive AZA subcutaenously once a day for 5 days as follows:~1. 5 mg/m\^2~2. 15 mg/m\^2~3. 30 mg/m\^2~4. 50 mg/m\^2~5. 75 mg/m\^2~Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). Subjects in Phase II will receive a dose that induces two of the three following:~1. a decrease DNA methylation levels in genes previously identified to be persistently hyper-methylated despite successful anti-TB therapy~2. an increase in TNF and IFN-γ signaling pathways~3. an increase in ex vivo mycobacterial growth inhibition assay"